Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
Centre for Fertility and Health, Norwegian Institute of Public Health, Skøyen, P.O. box 222, N-0213, Oslo, Norway.
Trials. 2023 Aug 12;24(1):520. doi: 10.1186/s13063-023-07508-5.
Timely detection and management of gestational diabetes mellitus (GDM) have been identified as a high priority for policymakers in low- and middle-income countries (LMICs). The GUIDES trial will evaluate a package of three interconnected film-based interventions aimed at improving the timely detection and management of GDM. The protocol for this trial has previously been published; this publication outlines the statistical analysis plan for the trial.
The GUIDES study is a multi-country cluster-randomised controlled trial consisting of one trial conducted in Uganda and one in India (30 clusters in each country). Mixed effects models will be used to compare the primary study outcomes of the proportion of women who are tested for GDM between 24 and 32 weeks of pregnancy and the mean fasting blood sugar of women with GDM at 34-week follow-up while accounting for clustering. Secondary analyses will compare the proportion of women with self-reported GDM diagnosis at 32 weeks of pregnancy and the proportion of women with adverse perinatal outcomes related to GDM up to 4 weeks after birth in each trial arm.
Follow-up is expected to end in March 2023 in Uganda and in May 2023 in India. Analyses will be carried out following this statistical analysis plan in the month following trial completion.
ClinicalTrials.gov NCT03937050. Registered on 3 May 2019. Clinical Trials Registry India CTRI/2020/02/023605. Registered on 26 February 2020.
及时发现和管理妊娠糖尿病(GDM)已被确定为中低收入国家(LMICs)政策制定者的高度优先事项。GUIDES 试验将评估一套三个相互关联的基于薄膜的干预措施,旨在改善 GDM 的及时发现和管理。该试验的方案先前已经发表过;本出版物概述了该试验的统计分析计划。
GUIDES 研究是一项多国家集群随机对照试验,包括在乌干达和印度进行的一项试验(每个国家有 30 个集群)。将使用混合效应模型来比较主要研究结果,即在 24 至 32 周妊娠期间接受 GDM 检测的女性比例,以及在 34 周随访时 GDM 女性的平均空腹血糖,同时考虑到聚类。次要分析将比较每个试验臂中在 32 周妊娠时自我报告的 GDM 诊断比例以及与 GDM 相关的不良围产期结局比例,直至分娩后 4 周。
预计乌干达的随访将于 2023 年 3 月结束,印度的随访将于 2023 年 5 月结束。分析将在试验完成后的一个月内按照本统计分析计划进行。
ClinicalTrials.gov NCT03937050. 于 2019 年 5 月 3 日注册。Clinical Trials Registry India CTRI/2020/02/023605. 于 2020 年 2 月 26 日注册。